MICA and NKG2D Variants As Risk Factors in Spondyloarthritis: a Case-control Study
Overview
Authors
Affiliations
The major histocompatibility complex class I polypeptide-related sequence A (MICA) glycoprotein mediates the activation of the natural killer group 2D receptor (NKG2D) expressed on NK and CD8+ T cells. A methionine or valine at position 129 in exon 3 results in strong (MICA129 met) or weak (MICA129 val) binding to NKG2D. The MICA A5.1 allele causes a premature stop codon. Various NKG2D polymorphisms are associated with low (NKC3 C/C and NKC4 C/C) or high (NKC3 G/G and NKC4 T/T) levels of NK cell cytotoxic activity. In 162 patients with spondyloarthritis (115 with ankylosing spondyloarthritis, 46 with psoriatic arthritis and 1 with reactive arthritis) compared to 124 healthy controls, MICA-129 with methionine allele was more frequent in patients with spondyloarthritis (odds ratio (OR) (95% confidence interval) = 4.84 (2.75‒8.67)), whereas MICA-129 val/val, MICA A5.1 and NKC3 C/C variants were less frequent (OR = 0.20 (0.11‒0.37), 0.15 (0.06‒0.36) and 0.24 (0.13‒0.44), respectively). After adjustment for HLA-B*27 status, only NKC3 C/C remained linked to spondyloarthritis (adjusted OR = 0.14 (0.06‒0.33)). Homozygosity for MICA A5.1 is linked to ankylosing spondyloarthritis, and NKC3 C/C and MICA-129 val/val to psoriatic arthritis. MICA and NKC3 polymorphisms (related to a low NK cell cytotoxic activity) constituted a genetic association with spondyloarthritis.
Current characteristics of a population of psoriatic arthritis and gender disparities.
Menis J, Doussiere M, Touboul E, Barbier V, Sobhy-Danial J, Fardellone P J Clin Transl Res. 2023; 9(2):84-92.
PMID: 37034001 PMC: 10075088.
Adhikari B, Starkweather A, Xu W, Acabchuk R, Ramesh D, Eze B Pilot Feasibility Stud. 2022; 8(1):142.
PMID: 35794661 PMC: 9260994. DOI: 10.1186/s40814-022-01103-2.
Chimenti M, Perricone C, DAntonio A, Ferraioli M, Conigliaro P, Triggianese P Front Genet. 2021; 12:671976.
PMID: 34447407 PMC: 8383732. DOI: 10.3389/fgene.2021.671976.
NKG2D Natural Killer Cell Receptor-A Short Description and Potential Clinical Applications.
Siemaszko J, Marzec-Przyszlak A, Bogunia-Kubik K Cells. 2021; 10(6).
PMID: 34200375 PMC: 8229527. DOI: 10.3390/cells10061420.
Machuldova A, Holubova M, Caputo V, cedikova M, Jindra P, Houdova L Front Immunol. 2021; 12:651751.
PMID: 33868289 PMC: 8044845. DOI: 10.3389/fimmu.2021.651751.